13603-45-7

Basic information

• Product Name: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE
• Synonyms: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE;2,6-Dimethyl-3-nitro-4-pyridinol;2,6-DiMethyl-3-nitropyridin-4-ol;2,6-DiMethyl-4-hydroxy-3-nitropyridine
• CAS NO: 13603-45-7
• Molecular Formula: C7H8N2O3
• Molecular Weight: 168.15
• Mol File: 13603-45-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 296 °C
• Boiling Point: 363.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.340±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.15±0.33(Predicted)
• CAS DataBase Reference: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(13603-45-7)
• EPA Substance Registry System: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(13603-45-7)

Safety Data

• Hazardous Substances Data: 13603-45-7(Hazardous Substances Data)

Usage

General Description

4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE, also known as NDMP, is a chemical compound with the molecular formula C7H8N2O3. It is a yellow crystalline solid that is insoluble in water but soluble in organic solvents. NDMP is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various dyes and pigments. NDMP is a nitro-substituted pyridine derivative and is known for its high reactivity and potential as a precursor for various chemical processes and applications.

Upstream product

• 13603-44-6 2,6-dimethylpyridin-4-ol 
• 92247-78-4 1-benzyl-2,6-dimethyl-1H-pyridin-4-one 
• 1004-36-0 2,6-dimethylpyrone 
• 7516-31-6 2,6-dimethyl-1H-pyridin-4-one 

Downstream Products

• 409316-67-2 3-amino-2,6-dimethylpyridin-4-ol 
• 15513-48-1 4-chloro-2,6-dimethyl-3-nitropyridine 
• 328554-54-7 2,6-dimethyl-4-(4-fluorophenylamino)-3-nitropyridine 
• 328554-55-8 3-amino-2,6-dimethyl-4-(4-fluorophenylamino)pyridine 

Relevant articles and documents

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 3. Discovery of a novel series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas with weak toxicological effects on adrenal glands

A series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O- acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'- aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.